AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington’s disease mouse model
Brain · 2023
DOI: 10.1093/brain/awac458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2023. Verfasst von Sarah B Thomson und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Centre for Molecular Medicine & Therapeutics, University of British Columbia and BC Children's Hospital, Vancouver, B…. Hauptthemen laut MEDLINE: Huntington Disease, MicroRNAs. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: uniQure Biopharma B.V., Huntington Society of Canada, Alzheimer Society Research Program.
Abstract (Originalsprache)
Huntingtin (HTT)-lowering therapies show great promise in treating Huntington’s disease. We have developed a microRNA targeting human HTT that is delivered in an adeno-associated serotype 5 viral vector (AAV5-miHTT), and here use animal behaviour, MRI, non-invasive proton magnetic resonance spectroscopy and striatal RNA sequencing as outcome measures in preclinical mouse studies of AAV5-miHTT. The effects of AAV5-miHTT treatment were evaluated in homozygous Q175FDN mice, a mouse model of Huntington’s disease with severe neuropathological and behavioural phenotypes. Homozygous mice were used instead of the more commonly used heterozygous strain, which exhibit milder phenotypes. Three-month-old homozygous Q175FDN mice, which had developed acute phenotypes by the time of treatment, were injected bilaterally into the striatum with either formulation buffer (phosphate-buffered saline + 5% sucrose), low dose (5.2 × 109 genome copies/mouse) or high dose (1.3 × 1011 genome copies/mouse) AAV5-miHTT. Wild-type mice injected with formulation buffer served as controls. Behavioural assessments of cognition, T1-weighted structural MRI and striatal proton magnetic resonance spectroscopy were performed 3 months after injection, and shortly afterwards the animals were sacrificed to collect brain tissue for protein and RNA analysis. Motor coordination was assessed at 1-month intervals beginning at 2 months of age until sacrifice. Dose-dependent changes in AAV5 vector DNA level, miHTT expression and mutant HTT were observed in striatum and cortex of AAV5-miHTT-treated Huntington’s disease model mice. This pattern of microRNA expression and mutant HTT lowering rescued weight loss in homozygous Q175FDN mice but did not affect motor or cognitive phenotypes. MRI volumetric analysis detected atrophy in four brain regions in homozygous Q175FDN mice, and treatment with high dose AAV5-miHTT rescued this effect in the hippocampus. Like previous magnetic resonance spectroscopy studies in Huntington’s disease patients, decreased total N-acetyl aspartate and increased myo-inositol levels were found in the striatum of homozygous Q175FDN mice. These neurochemical findings were partially reversed with AAV5-miHTT treatment. Striatal transcriptional analysis using RNA sequencing revealed mutant HTT-induced changes that were partially reversed by HTT lowering with AAV5-miHTT. Striatal proton magnetic resonance spectroscopy analysis suggests a restoration of neuronal function, and striatal RNA sequencing analysis shows a reversal of transcriptional dysregulation following AAV5-miHTT in a homozygous Huntington’s disease mouse model with severe pathology. The results of this study support the use of magnetic resonance spectroscopy in HTT-lowering clinical trials and strengthen the therapeutic potential of AAV5-miHTT in reversing severe striatal dysfunction in Huntington’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Genetics, Centre for Molecular Medicine & Therapeutics, University of British Columbia and BC Children's Hospital, Vancouver, BC V5Z4H4, Canada.
- Department of Research & Development, uniQure Biopharma B.V., 1105BP Amsterdam, The Netherlands.
- Department of Translational Biology, IRBM S.p.A., Pomezia 00071, Italy.
- UBC MRI Research Centre, Department of Radiology, University of British Columbia, Vancouver, BC V6T2B5, Canada.
- Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27101, USA.
- School of Engineering Science, Simon Fraser University, Burnaby, BC V5A0A7, Canada.
ORCID-Profile: Sarah B Thomson
Förderung
- uniQure Biopharma B.V.
- Huntington Society of Canada
- Alzheimer Society Research Program
- Alzheimer Society of Canada
- Natural Sciences and Engineering Research Council of Canada
- Canadian Institutes of Health Research
- Michael Smith Foundation for Health Research
Zitieren
APA
Thomson, S. B., Stam, A., Brouwers, C., Fodale, V., Bresciani, A., Vermeulen, M., Mostafavi, S., Petkau, T. L., Hill, A., Yung, A., Russell-Schulz, B., Kozlowski, P., MacKay, A., Ma, D., Beg, M. F., Evers, M. M., Vallès, A., & Leavitt, B. R. (2023). AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington’s disease mouse model. Brain. https://doi.org/10.1093/brain/awac458
Vancouver
Thomson SB, Stam A, Brouwers C, Fodale V, Bresciani A, Vermeulen M, et al. AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington’s disease mouse model. Brain. 2023. doi:10.1093/brain/awac458
BibTeX
@article{Thomson2023,
author = {Thomson, Sarah B and Stam, Anouk and Brouwers, Cynthia and Fodale, Valentina and Bresciani, Alberto and Vermeulen, Michael and Mostafavi, Sara and Petkau, Terri L and Hill, Austin and Yung, Andrew and Russell-Schulz, Bretta and Kozlowski, Piotr and MacKay, Alex and Ma, Da and Beg, Mirza Faisal and Evers, Melvin M and Vallès, Astrid and Leavitt, Blair R},
title = {AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington’s disease mouse model},
journal = {Brain},
year = {2023},
doi = {10.1093/brain/awac458}
}
EUVIMED